My Profile
Edit Profile
My Follows
My Wires
My Drafts
Analytics
Email Preferences
Sign Out
home
Latest
Shares
ETFs
Retirement
Markets
Buy Hold Sell
Topics
Alternatives
Exchange Traded Funds (ETFs)
Growth
Income
Markets
Property
Retirement
Shares
Wealth
Shows
Ask an Adviser
Buy Hold Sell
Expert Insights
Fund in Focus
Rapid Fire
Success and More Interesting Stuff
The Rules of Investing
Series
Listed Series
Livewire Live
Meet The Investor
Outlook Series
Reporting Season
Contributors
Find Funds
Newsletter
About Livewire
Advertising
Careers
Contact Us
Write a Wire
Notifications
Loading...
Write a wire
Account
My profile
My follows
My wires
My drafts
Analytics
Email preferences
Company
About Livewire
Advertising
Contact us
Sign out
Sign In
Join Free
Latest
Shares
ETFs
Retirement
Markets
Buy Hold Sell
Find funds
Newsletter
Topics
Alternatives
Exchange Traded Funds (ETFs)
Growth
Income
Markets
Property
Retirement
Shares
Wealth
Shows
Ask an Adviser
Buy Hold Sell
Expert Insights
Fund in Focus
Rapid Fire
Success and More Interesting Stuff
The Rules of Investing
Series
Listed Series
Livewire Live
Meet The Investor
Outlook Series
Reporting Season
Categories
Asset Allocation
Commodities
Daily Report
Education
Equities
Fixed Income
Funds
Investment Theme
Macro
Private Markets
Property
Weekend Report
Find Funds
Contributors
Newsletter
About Livewire
Advertising
Careers
Contact Us
Market Wraps
life sciences
Latest news and analysis on life sciences
August 30, 2016 17:14
A potentially investable mental health breakthough
Stuart Roberts
Pitt Street Research and NDF Research
August 30, 2016 17:14
August 26, 2016 16:10
The Coming Boom in Life Sciences in Australia
Stuart Roberts
Pitt Street Research and NDF Research
August 26, 2016 16:10
August 22, 2016 06:29
Lifesciences: Give your portfolio a booster
shot
Buy Hold Sell
Livewire Markets
August 22, 2016 06:29
Advertisement
March 25, 2014 12:31
dorsaVi (ASX:DVL) is walking around with an impressive update on the commercialisation of its movement products
Matthijs Smith
Canaccord Genuity Australia
March 25, 2014 12:31
December 02, 2013 12:44
@morgans rate Impedimed (IPD, Outperform, Price Target A$0.30)
Livewire Equities
Livewire
December 02, 2013 12:44
November 13, 2013 10:20
@morgans have an outperform rating on Impedimed (IPD) note from Scott Power follows
Livewire Equities
Livewire
November 13, 2013 10:20
October 30, 2013 15:30
Livewire spoke with specialist Life Sciences analyst Scott Power (RBS Morgans) following the recent AusBiotech conference in Melbourne
Livewire Exclusive
Livewire Markets
October 30, 2013 15:30
61-67 of 67
1
2
3
4
5
6
7
most
popular
Buy Hold Sell
Buy Hold Sell: 6 ASX stocks built to handle tough
conditions
Patrick Poke,
Livewire Markets
Equities
Question everything
Martin Conlon,
Schroders
Buy Hold Sell
Buy Hold Sell: 5 ASX ‘stayers’ to go the
distance
Patrick Poke,
Livewire Markets
Income
10 best ASX dividend stocks and income ETFs for 2027
Vishal Teckchandani,
Livewire Markets
view all
Advertisement
